The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting
Open accessAbstract
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, metastasis and therapy resistance. In particular, this review will focus on the interactions between cell receptor ligands and fibronectin and how this interaction influences downstream signaling events that aid tumor progression. This review will further discuss the possible implications of therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated that these studies will set a basis for future research that will not only aid understanding of fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Mesothelial Cells Promote Early Ovarian Cancer Metastasis through Fibronectin Secretion
Kenny, H. A., Chiang, C.-Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L., Ladanyi, A., Penicka, C. V., George, J., Matlin, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74778 · Cited by 303
Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape
Endoh, T., & Ohtsuki, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.005 · Cited by 242
Nam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196
François, R. A., Maeng, K., Nawab, A., Kaye, F. J., Hochwald, S. N., & Zajac-Kaye, M. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv123 · Cited by 48
Cited by
Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin
Erdogan, B., Ao, M., White, L. M., Means, A. L., Brewer, B. M., Yang, L., Washington, M. K., Shi, C., Franco, O. E., Weaver, A. M., et al. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201704053 · Cited by 552
“Aberrant expression of Fn and its fetal isoforms have been reported in many cancers (Bae et al., 2013; Topalovski and Brekken, 2016; Gopal et al., 2017; Wang and Hielscher, 2017).”
Chan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Self-citationExtracellular Matrix Alterations in Metastatic Processes
Paolillo, M., & Schinelli, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194947 · Cited by 377
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., & Falfan-Valencia, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.010 · Cited by 373
C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 275
Metadata
- Authors
- Wang, J. P., & Hielscher, A.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2017
- Volume
- 8
- Issue
- 4
- Pages
- 674-682
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W2594338562
- Cited by
- 167
- References
- 6
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.